Clinical and molecular factors for selection of nivolumab or irinotecan as third-line treatment for advanced gastric cancer

Clinical and molecular factors for selection of nivolumab or irinotecan as third-line treatment for advanced gastric cancer

Background: The use of nivolumab or irinotecan as the third-line treatment for patients with advanced gastric cancer (AGC) remains controversial. Methods: This study analyzed patients with AGC treated with nivolumab or irinotecan (nivolumab group or irinotecan group, respectively) from May 2016 to A...

Full description

Bibliographic Details
Main Authors: Takahiro Ishii, Akihito Kawazoe, Akinori Sasaki, Saori Mishima, Sawada Kentaro, Yoshiaki Nakamura, Daisuke Kotani, Yasutoshi Kuboki, Hiroya Taniguchi, Takashi Kojima, Toshihiko Doi, Takayuki Yoshino, Takeshi Kuwata, Genichiro Ishii, Kohei Shitara
Format: Article
Language:English
Published: SAGE Publishing 2020-07-01
Series:Therapeutic Advances in Medical Oncology
Online Access:https://doi.org/10.1177/1758835920942377

Internet

https://doi.org/10.1177/1758835920942377

Similar Items